Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026)
Aytu Biopharma (AYTU) reported Income from Continuing Operations of 5618000.0 for Q1 2026, down 243.39% year-over-year from 3918000.0 in Q1 2025, and up 46.92% quarter-over-quarter from 10584000.0 in Q4 2025.
Aytu Biopharma (AYTU) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has 17 years of Income from Continuing Operations data on file, last reported at 5618000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 5618000.0, down 243.39% year-over-year; the trailing twelve-month figure through Mar 2026 was 34117000.0 (down 1558.61% YoY), and the FY2025 annual result was 14182000.0, down 13.66% from the prior year.
- Income from Continuing Operations rose to 5618000.0 in Q1 2026 per AYTU's latest filing, from 10584000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3918000.0 in Q1 2025 and troughed at 53291000.0 in Q1 2022.
- A 5-year average of 7498588.24 and a median of 3337000.0 in 2024 frame the typical range for Income from Continuing Operations.
- On a YoY basis, Income from Continuing Operations climbed as much as 272.83% in 2025 and fell as far as 1691.58% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 6693000.0 in 2022, then surged by 108.95% to 599000.0 in 2023, then rose by 11.02% to 665000.0 in 2024, then sank by 1691.58% to 10584000.0 in 2025, then soared by 46.92% to 5618000.0 in 2026.
- Business Quant data shows AYTU's Income from Continuing Operations at 5618000.0 in Q1 2026, 10584000.0 in Q4 2025, and 1965000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Aytu Biopharma | 24.60 Mn | -2.12 Mn | 7.60 Mn | -5.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.62 Mn |
| Dec 31, 2025 | -10.58 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | -19.88 Mn |
| Mar 31, 2025 | 3.92 Mn |
| Dec 31, 2024 | 665,000.00 |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | -3.34 Mn |
| Mar 31, 2024 | -2.27 Mn |
| Dec 31, 2023 | 599,000.00 |
| Sep 30, 2023 | -7.47 Mn |
| Jun 30, 2023 | -2.58 Mn |
| Mar 31, 2023 | -7.20 Mn |
| Dec 31, 2022 | -6.69 Mn |
| Sep 30, 2022 | -701,000.00 |
| Jun 30, 2022 | -16.09 Mn |
| Mar 31, 2022 | -53.29 Mn |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -27.85 Mn |
| Jun 30, 2021 | -18.74 Mn |